Company Filing History:
Years Active: 2009
Title: **Innovative Contributions of Inventor Yan Ma in Lung Cancer Research**
Introduction
Yan Ma, an accomplished inventor based in Beverly, Massachusetts, has made significant strides in the field of lung cancer research. With a focus on genetic engineering and transgenic models, his work aims to deepen the understanding of lung tumorigenesis and pave the way for potential therapeutic interventions.
Latest Patents
Yan Ma holds one patent titled "Transgenic non-human animal model of lung tumorigenesis." This innovative invention describes a transgenic non-human animal that possesses a genome containing a transgene encoding a cyclin E protein, which is operably linked to a lung-specific promoter. The transgenic animals developed through this invention exhibit increased levels of cyclin E protein in the lung and demonstrate a heightened occurrence of lung carcinogenesis. Moreover, these animals showed elevated levels of Gli1 and Shh, further contributing to the understanding of lung cancer mechanisms. The patent also provides vectors, cells, and cell lines, as well as a method for identifying therapeutic agents for the chemoprevention or treatment of lung cancer.
Career Highlights
Yan Ma is currently affiliated with Dartmouth College, where he collaborates with several noted researchers in the field. His work exemplifies a fusion of innovative science and practical application aimed at combating one of the most challenging forms of cancer. His commitment to advancing research in oncology sets a strong precedent for future discoveries in the medical field.
Collaborations
During his career, Yan Ma has collaborated with prominent figures like Ethan Dmitrovsky and Sarah Freemantle. These collaborations highlight the importance of teamwork in scientific research and emphasize the synergy created through combining varying expertise and perspectives.
Conclusion
In summary, Yan Ma's contributions to the field of lung cancer research through his patented transgenic animal model are significant. By serving as a platform for understanding tumorigenesis and potential treatments, his work not only enriches scientific knowledge but also opens pathways for future innovation in cancer therapeutics.